专科多学科委员会可改善肉瘤患者生存
治疗前提交者指南依从性更好、再手术更少,无局部复发生存和无复发生存均显著更优。
要点
- 肉瘤患者初始治疗前提交专科MDTB与更好的指南依从性相关。
- 治疗前MDTB讨论与更少的再手术及更优的无复发生存相关。
- 全国性强制MDTB和二次病理复核可改善肉瘤管理质量。
核心结论
- 初始治疗由治疗前专科MDTB指导时,肉瘤患者的指南依从性和无复发生存显著更好。
研究设计与样本
- NETSARC为法国国家癌症研究所资助的26个专科肉瘤中心网络,设有专科MDTB。
- 2010年起法国肉瘤患者必须提交MDTB并进行二次病理复核。
主要发现
- 5281例(42.2%)在治疗开始前提交MDTB,7247例(57.8%)在治疗开始后提交。
- 治疗前提交MDTB组总体预后特征更差。
- 治疗前提交MDTB与更好的指南依从性相关,包括术前活检、影像、初始手术质量和更少再手术(均P<0.001)。
- 治疗前提交MDTB组无局部复发生存和无复发生存单变量及多变量分析均显著更优。
临床怎么用
- 肉瘤患者初始治疗前应提交专科MDTB讨论,并完成二次病理复核。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sarcomas are rare but aggressive diseases. Specialized multidisciplinary management is not implemented for all patients in most countries. We investigated the impact of a multidisciplinary tumor board (MDTB) presentation before treatment in a nationwide study over 5 years. PATIENTS AND METHODS: NETSARC (netsarc.org) is a network of 26 reference sarcoma centers with specialized MDTB, funded by the French National Cancer Institute to improve the outcome of sarcoma patients. Since 2010, presentation to an MDTB and second pathological review are mandatory for sarcoma patients in France. Patients' characteristics and follow-up are collected in a database regularly monitored and updated. The management and survival of patients presented to these MDTB before versus after initial treatment were analyzed. RESULTS: Out of the 12 528 patients aged ≥15 years, with a first diagnosis of soft tissue and visceral sarcoma obtained between 1 January 2010 and 31 December 2014, 5281 (42.2%) and 7247 (57.8%) were presented to the MDTB before and after the initiation of treatment, respectively. The former group had generally worse prognostic characteristics. Presentation to a MDTB before treatment was associated with a better compliance to clinical practice guidelines, for example, biopsy before surgery, imaging, quality of initial surgery, and less reoperations (all P < 0.001). Local relapse-free survival and relapse-free survival were significantly better in patients presented to a MDTB before initiation of treatment, both in univariate and multivariate analysis. CONCLUSION: The compliance to clinical practice guidelines and relapse-free survival of sarcoma patients are significantly better when the initial treatment is guided by a pre-therapeutic specialized MDTB.
引用
- Blay JY, Soibinet P, Penel N, et al. Improved survival using specialized multidisciplinary board in sarcoma patients. Ann Oncol. 2017. PMID: 29117335. doi:10.1093/annonc/mdx484
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。